N‐acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of heart failure
暂无分享,去创建一个
D. Kaye | S. Kuruppu | Xiaojun Du | H. Kiriazis | N. Rajapakse | P. Chu | D. Horlock | Beverly Giam | A. Smith
[1] Y. Duan,et al. N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition , 2015, BMC Cardiovascular Disorders.
[2] D. Kaye,et al. Augmented endothelial l‐arginine transport ameliorates pressure‐overload‐induced cardiac hypertrophy , 2015, Experimental physiology.
[3] B. C. Bernardo,et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets , 2015, Archives of Toxicology.
[4] N. Rajapakse,et al. Endothelial cationic amino acid transporter‐1 overexpression can prevent oxidative stress and increases in arterial pressure in response to superoxide dismutase inhibition in mice , 2014, Acta physiologica.
[5] M. Salarifar,et al. N-Acetylcysteine Effects on Transforming Growth Factor-β and Tumor Necrosis Factor-α Serum Levels as Pro-Fibrotic and Inflammatory Biomarkers in Patients Following ST-Segment Elevation Myocardial Infarction , 2013, Drugs in R&D.
[6] Tevfik F Ismail,et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.
[7] P. Gao,et al. Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice , 2013, Acta Pharmacologica Sinica.
[8] H. Shimokawa,et al. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. , 2012, Journal of cardiology.
[9] L. Mulligan,et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. , 2012, Journal of the American College of Cardiology.
[10] H. Krum,et al. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. , 2012, Cardiovascular therapeutics.
[11] D. Kaye,et al. CXCR4 Antagonism Attenuates the Cardiorenal Consequences of Mineralocorticoid Excess , 2011, Circulation. Heart failure.
[12] V. Eder,et al. Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. , 2011, Cardiovascular research.
[13] Yanjie Lu,et al. Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFβ1 expression and activation of p38‐MAPK and ERK1/2 , 2011, British journal of pharmacology.
[14] M. Frenneaux,et al. Antioxidant treatment for heart failure: friend or foe? , 2009, QJM : monthly journal of the Association of Physicians.
[15] I. Efimov,et al. Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms , 2009, Circulation.
[16] Yao Sun,et al. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats , 2008, Molecular and Cellular Biochemistry.
[17] P. Mulder,et al. Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. , 2007, Journal of molecular and cellular cardiology.
[18] Yao Sun. Oxidative stress and cardiac repair/remodeling following infarction. , 2007, The American journal of the medical sciences.
[19] R. Erbel,et al. Bidirectional Role of Tumor Necrosis Factor-&agr; in Coronary Microembolization: Progressive Contractile Dysfunction Versus Delayed Protection Against Infarction , 2007, Circulation research.
[20] Ajay M Shah,et al. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure , 2006, Heart.
[21] A. Marian,et al. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. , 2006, Journal of the American College of Cardiology.
[22] P. Doevendans,et al. Myocyte apoptosis in heart failure. , 2005, Cardiovascular research.
[23] J. Zicha,et al. Chronic N-Acetylcysteine Administration Prevents Development of Hypertension in Nω-Nitro-L-Arginine Methyl Ester-Treated Rats: The Role of Reactive Oxygen Species , 2005, Hypertension Research.
[24] F. Roudot-thoraval,et al. N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-&agr; Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats , 2004, Circulation.
[25] S. Vatner,et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. , 2003, The Journal of clinical investigation.
[26] P. Singal,et al. Oxidative Stress and Apoptosis in Heart Dysfunction , 2002, Herz.
[27] P. Anversa,et al. Oxidative Stress–Mediated Cardiac Cell Death Is a Major Determinant of Ventricular Dysfunction and Failure in Dog Dilated Cardiomyopathy , 2001, Circulation research.
[28] A. Dart,et al. beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. , 2000, Circulation.
[29] Per Capita,et al. About the authors , 1995, Machine Vision and Applications.
[30] W. H. Betts,et al. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. , 1995, Circulation.
[31] J. McMurray,et al. Evidence of oxidative stress in chronic heart failure in humans. , 1993, European heart journal.
[32] J. Mariani,et al. Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. , 2010, The American journal of pathology.
[33] Stefano Geuna,et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. , 2008, Endocrinology.
[34] Hiroyuki Tsutsui,et al. [Oxidative stress and heart failure]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[35] B. Greenberg,et al. Molecular Medicine Tumor Necrosis Factor-�–Induced AT 1 Receptor Upregulation Enhances Angiotensin II–Mediated Cardiac Fibroblast Responses That Favor Fibrosis , 2022 .